AbbVie Stock in Focus with Strategic Cerevel Acquisition

By Richard Mason


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.

AbbVie Logo on white smartphone screen next to syringes and pills.
New Growth Path for AbbVie Stock After Cerevel Deal

What You Need To Know

AbbVie Inc (NYSE: ABBV), a prominent pharmaceutical company, announced its plan to acquire Cerevel Therapeutics, a neuroscience drugmaker, for approximately $8.7 billion. This acquisition, set to finalize in mid-2024, involves AbbVie purchasing Cerevel's shares at $45 each. Following the announcement, Cerevel's shares rose 16% to nearly $43, while AbbVie's shares saw a slight dip of less than 1%.

This strategic move marks AbbVie's continued efforts to diversify and strengthen its drug portfolio, especially as some of its top-selling drugs, like Humira, encounter generic competition.

Read: AbbVie Stock Analysis: Is ABBV a Good Investment?

This acquisition follows closely on the heels of AbbVie's recent agreement to purchase Immunogen, a cancer drug developer, for about $10 billion.

Cerevel's addition to AbbVie's portfolio is particularly significant in the area of psychiatric and neurological disorders, where there are considerable unmet medical needs. One of Cerevel's key drugs is Emraclidine, an experimental treatment targeting schizophrenia and Alzheimer’s disease psychosis, currently undergoing phase one study.

Richard Gonzalez, AbbVie's CEO and chairman, highlighted the potential growth opportunities this merger offers, extending well into the next decade. He emphasized AbbVie's intent to utilize its extensive commercial, international, regulatory, and clinical expertise to maximize shareholder value and realize the multibillion-dollar sales potential of Cerevel's assets.

Read: The Value of Understanding IP For an Investor

Sign up for Investing Intel Newsletter

Why This Is Important for Retail Investors

  1. Portfolio Diversification: AbbVie's acquisition of Cerevel Therapeutics represents a strategic expansion into the neuroscience segment, diversifying its portfolio beyond its current top-selling treatments. For retail investors, this diversification can signal a more resilient company profile, potentially reducing investment risk associated with reliance on a limited range of products.

  2. Growth Opportunities: The addition of Cerevel's drug pipeline, especially in areas like schizophrenia and Alzheimer’s disease psychosis, opens up new avenues for growth. Investors might find this appealing as it indicates potential for increased revenue and profitability in the future, especially given the high demand and unmet needs in these therapeutic areas.

  3. Enhanced Market Position: By acquiring a company with promising experimental treatments, AbbVie strengthens its position in the competitive pharmaceutical market. For retail investors, investing in a company with a strong market position can be a prudent choice, as it often leads to more stable and consistent returns.

  4. Long-term Revenue Potential: With the acquisition of Cerevel, AbbVie is not just expanding its current product range but is also investing in future revenue streams. The potential multibillion-dollar sales from Cerevel’s drug portfolio present an attractive prospect for retail investors looking for long-term growth and profitability.

  5. Response to Generic Competition: As AbbVie’s top-selling drugs face generic competition, the company's proactive approach in acquiring new assets to bolster its pipeline shows a strategic response to market challenges. For retail investors, a company that actively manages its business risks and adapts to market dynamics can be a more reliable investment choice.

How Can You Use This Information?

Here are some of the investing ideas that can be explored using this information:

Growth Investing

The acquisition signals growth potential for AbbVie, particularly in the expanding field of neuroscience. Investors looking for growth opportunities might see the potential for increased revenue and market share from new drug developments and the expansion into new therapeutic areas.

Growth investing focuses on stocks of companies expected to grow at an above-average rate compared to other stocks in the market; learn more in our article titled 'What is Growth Investing?'.

Momentum Investing

ABBV stock is down 9.8% YTD so investors will be hoping this news gives it an overdue boost. Momentum investors might consider AbbVie stock. This strategy would bank on pivoting to an upward trajectory for ABBV stock, driven by investor enthusiasm and the anticipated success of the acquisition.

Momentum investing rides the wave of existing market trends by buying assets that have shown an upward price trend and selling those in a downtrend.

Dividend Investing

AbbVie has a history of paying dividends. Investors interested in steady income streams might find AbbVie appealing, especially as the acquisition could strengthen its financial position and ability to maintain or increase dividend payouts.

Dividend investing targets companies that regularly distribute a portion of their earnings to shareholders as dividends.

Defensive investing

Pharmaceuticals are often considered a defensive sector since demand for healthcare and medication remains stable even during economic downturns. Investors looking for lower-risk investments might view AbbVie stock as a suitable option, particularly with its diversified and strengthened portfolio post-acquisition.

Defensive Investing focuses on securing a portfolio by choosing companies that are less sensitive to economic downturns.

Read What Others Are Saying

What you should read next:

Investing with Insight

Knowing where to invest is not easy. Bullish and bearish sentiment is always vying for control, and investors like you can very quickly become overwhelmed.

And yet, no matter what the wider stock market is doing, there are always little-known gems to uncover. 

One potential growth stock flying under the radar is a dynamic company operating at the forefront of the entertainment industry. This business is diverse and multifaceted and led by industry veterans with extensive experience in entertainment and investment.

This high-potential US stock is targeting India’s tech-hungry 1.4 billion people.

Internet and social media adoption in India is surging, and the country has the LARGEST youth population worldwide. Over 650M people are under 25 years old, and 850M are under 35 years old. 

With rising economic and educational prospects, the country is a hotbed for digital engagement.

Some highlights you’ll want to know include:

  • This is one of the fastest-growing creator-media companies in India and the United States.

  • This company reaches 1 billion global consumers every month.

  • India was the second-fastest-growing market in the influencer marketing space in 2022. 

  • Global influencer marketing spend is expected to reach $34 billion in 2023.

  • This company has posted nine consecutive quarters of YoY growth, representing a 33% CAGR using its repeatable content strategy.

  • This impressive small-cap has just appointed a former TikTok Country manager as its India Group CEO. 

Finally, this stock is analyst-backed with a potential 114% upside from the analyst initiation date.

If you're intrigued by this stock’s promising prospects, why not take a closer look?


In this article:



Author: Richard Mason

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Richard Mason does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Richard Mason has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter